D.E. Shaw & Co
CSTL icon

D.E. Shaw & Co’s Castle Biosciences CSTL Stock Holding History

D.E. Shaw & Co’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.2M Buy
211,966
+52,257
+33% +$1.71M ﹤0.01% 2141
2025
Q4 		$6.21M Buy
159,709
+67,095
+72% +$2.16M ﹤0.01% 2129
2025
Q3 		$2.11M Sell
92,614
-55,576
-38% -$1.13M ﹤0.01% 2942
2025
Q2 		$3.03M Sell
148,190
-40,987
-22% -$759K ﹤0.01% 2421
2025
Q1 		$3.79M Buy
189,177
+98,614
+109% +$2.44M ﹤0.01% 2112
2024
Q4 		$2.41M Buy
+90,563
New +$2.76M ﹤0.01% 2583
2024
Q2 		– Sell
-13,382
Closed -$296K – 4536
2024
Q1 		$296K Sell
13,382
-38,982
-74% -$848K ﹤0.01% 3733
2023
Q4 		$1.13M Buy
+52,364
New +$922K ﹤0.01% 3057
2023
Q1 		– Sell
-28,937
Closed -$681K – 4525
2022
Q4 		$681K Buy
28,937
+1,405
+5% +$32.6K ﹤0.01% 3683
2022
Q3 		$718K Buy
+27,532
New +$772K ﹤0.01% 3818
2021
Q4 		– Sell
-7,104
Closed -$472K – 5458
2021
Q3 		$472K Buy
+7,104
New +$500K ﹤0.01% 4118
2021
Q2 		– Sell
-19,153
Closed -$1.31M – 4780
2021
Q1 		$1.31M Buy
19,153
+64
+0.3% +$4.81K ﹤0.01% 2905
2020
Q4 		$1.28M Buy
19,089
+10,492
+122% +$569K ﹤0.01% 2867
2020
Q3 		$442K Sell
8,597
-8,854
-51% -$394K ﹤0.01% 3285
2020
Q2 		$658K Buy
+17,451
New +$596K ﹤0.01% 3181

Other funds holding CSTL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
SPPAM
Summit Partners Public Asset Management Boston, Massachusetts $3.72B AUM 162.29% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co's CSTL Position: Q1 2026 in Review

D.E. Shaw & Co increased its Castle Biosciences (CSTL) stake by 33% in Q1 2026, buying an estimated $1.71M and bringing the position to 211,966 shares worth $5.2M. The position accounts for ﹤0.01% of the portfolio, ranked #2141.

D.E. Shaw & Co first reported a position in CSTL in Q2 2020 and has held it in 15 quarters since. The position peaked at $6.21M in Q4 2025. 186 funds tracked by Wall St. Rank hold CSTL as of Q1 2026.

  • D.E. Shaw & Co held 211,966 shares of Castle Biosciences worth $5.2M as of Q1 2026.
  • D.E. Shaw & Co bought 52,257 Castle Biosciences shares in Q1 2026, an estimated $1.71M.
  • Castle Biosciences made up ﹤0.01% of D.E. Shaw & Co's portfolio in Q1 2026, its #2141 holding.
  • D.E. Shaw & Co first reported a position in Castle Biosciences in Q2 2020 and has held it in 15 quarters since.
  • D.E. Shaw & Co's Castle Biosciences position peaked at $6.21M in Q4 2025.
  • 186 funds tracked by Wall St. Rank held Castle Biosciences as of Q1 2026.

Based on D.E. Shaw & Co's 13F filing for Q1 2026, filed 15 May 2026.